Here is what actually happened today. It was quiet. No government agency announced anything new. No new law moved forward. The clearest thing to watch was the stock market, where the small handful of companies working on these medicines drifted in different directions. Compass Pathways, one of the leaders, rose about 2 percent. MindMed slipped about 4 percent. The others barely moved at all. There was no news to explain any of it — just the normal ebb and flow of a market holding its breath.
What everyone is really waiting for is one specific study. A company called Cybin is testing a version of psilocybin — the active ingredient in magic mushrooms, tweaked in the lab to last longer — as a treatment for serious depression. The results of that big trial are expected before the end of this year. If those results are good, they could move the whole field. If they disappoint, the mood sours fast.
Beneath the quiet, a clear pattern is forming. Right now, nothing is moving in Washington. There are no psychedelic bills getting a real hearing in Congress, and the political calendar is jammed with wildfires, floods, and other emergencies. So the energy has shifted to two places instead. One is the states — California in particular is building a path to let people legally access these treatments through trained providers. The other is the science itself. In a stalled political moment, it is the trial results, not the politicians, that will decide whether this field speeds up or waits. That Cybin study is the next real test. Even if it succeeds, regulators will almost certainly still ask for a second successful trial before approving anything — one good result is a strong start, not a finish line.
For the real people inside this story, the waiting is the hardest part. Think of someone with depression so deep that ordinary treatments have failed them again and again. Think of a veteran carrying trauma that talk therapy and standard pills have not touched. They read the headlines. They hear that a new kind of medicine might be coming. And then they hit a silence like today's, where nothing seems to happen. But this silence is not emptiness. It is the pause before an answer. The trial that will help decide their future is already running, its results already being gathered. The most hopeful and honest thing that can be said today is this: the door has not closed. It is quietly being built, one careful test at a time, and it is closer than a quiet day makes it feel.
What is being called in cannot be called back. The currents forming in legislation, in research, in culture — OOTW reads them daily, so you don't have to navigate them alone.
What is forming beneath the surface is always closer than it appears.
70%
No psychedelic drug review panel meeting set before December 2026
The FDA (the US drug regulator) holds public expert panels before approving major new drugs. No psychedelic company has yet submitted the full package of evidence the FDA needs to even schedule one of these panels. This means no psychedelic drug is close to formal federal approval right now.
→ The FDA approval process for psychedelics hasn't even reached the panel-review stage yet, so legal clinical access through that path is still years away.
Resolves: 2026-11-30 · USA
REGULATORY
the precise call ▾
No FDA advisory committee for any psychedelic NDA is scheduled or announced before 2026-11-30.. Absent a filed NDA with complete confirmatory data, there's nothing to convene on. The pipeline isn't at that stage yet.
68%
Congress won't vote on psychedelic laws this session; California leads instead
The US Congress is overwhelmed with other urgent issues — disaster relief, foreign policy crises — and psychedelic legislation can't get enough attention to move forward at the federal level this year. California is the one place where real legal progress on supervised psychedelic therapy is actually happening.
→ Federal psychedelic law is going nowhere in 2026; California is where the action is.
Resolves: 2026-12-31 · Global
LEGISLATION
the precise call ▾
No standalone psychedelic bill receives a House committee markup before the 2026 session recess; movement is confined to California's therapeutic access framework.. The docket is saturated with wildfire/flood/Venezuela priorities. Federal psychedelic action can't get floor time this cycle. State is where I can deliver.
65%
Congress skips psychedelic legislation again; California remains the only mover
Multiple perspectives — including lawmakers, veterans' advocates, and drug enforcement officials — all agree that federal psychedelic legislation won't get a formal committee vote or floor debate this congressional session. The only meaningful legal progress is happening at the state level in California.
→ Everyone who watches federal policy closely agrees: psychedelic law reform at the US national level isn't happening this year.
Resolves: 2027-02-13 · USA
LEGISLATION
the precise call ▾
No federal psychedelic bill gets committee markup or floor action this session; movement confined to California therapeutic access.. Consensus of 4 agents: legislator, veterans_advocate, dea_officer. 0 dissenting.
66%
Cybin's depression drug trial succeeds, but company still needs a second study
Cybin, a psychedelic drug company, is running a major clinical trial called APPROACH/EMBRACE for their drug CYB003 — a modified form of psilocin (the active ingredient in magic mushrooms) — in people with major depression (MDD). The trial is expected to show the drug meaningfully reduces depression symptoms. But even a clear win won't be enough: the FDA requires two separate successful trials before it will approve any drug, so Cybin still has more work to do.
→ Cybin's depression drug is showing real promise, but one successful trial gets them only halfway to FDA approval.
Resolves: 2026-12-31 · USA
CLINICAL
the precise call ▾
Cybin's CYB003 Phase 3 (APPROACH/EMBRACE) topline in MDD reports a statistically significant MADRS reduction on primary endpoint before year-end, but FDA will still require the second confirmatory study.. Deuterated analog durability data looks real, but my role demands two adequate well-controlled trials. One positive readout doesn't shortcut the NDA.
62%
Cybin's trial results will sharply move the whole psychedelic stock sector
When Cybin announces whether their depression drug trial worked, it won't just affect Cybin's own stock — it's expected to move the entire psychedelic investment sector by double digits (more than 10% up or down). That's because this is the highest-profile clinical result coming in 2026, and investors across the sector will react to what it signals about the future of psychedelic medicine as a whole.
→ Cybin's upcoming trial results are the single most important event for psychedelic stocks and the whole field in 2026.
Resolves: 2026-11-15 · Global
CAPITAL-MARKETS
the precise call ▾
CYB003 (deuterated psilocin, MDD) topline is the sector's next repricing event, producing a double-digit single-name move before year-end.. Consensus of 3 agents: fda_reviewer, maps_researcher, investor. 1 dissenting.